Advances in the treatment of gastrointestinal stromal tumor Journal Article
| Authors: | D'adamo, D. |
| Article Title: | Advances in the treatment of gastrointestinal stromal tumor |
| Abstract: | GIST (gastrointestinal stromal tumor) is a rare soft tissue malignancy arising in the gut. It has become well known recently because of the effectiveness of anti-KIT tyrosine kinase inhibitors. From a disease that 10 years ago was only treatable with surgery, now multiple phase 2 and phase 3 trials have identified active first-line systemic therapy, appropriate dosing, an active second-line agent, and established the role of adjuvant therapy after surgery for patients with intermediate- and high-risk tumors. These are accomplishments that took decades to achieve for other more common diseases such as breast cancer or lung cancer. GIST has been the ideal disease system for studying targeted therapy in solid tumors. The progress in treating GIST has come directly from the advances that have been made in the laboratory, understanding the basic biology of tyrosine kinases, the oncogenic activity of c-KIT, and how that enzymatic activity can be inhibited. By studying model diseases such as GIST, we should be able to develop paradigms to treat more common cancers as well. © 2009 Springer Healthcare Communications. |
| Keywords: | cancer survival; unclassified drug; clinical feature; clinical trial; fatigue; neutropenia; review; sorafenib; sunitinib; chemoembolization; diarrhea; dose response; drug dose comparison; drug dose reduction; drug efficacy; drug safety; drug withdrawal; antineoplastic agents; adjuvant therapy; combined modality therapy; anorexia; gastrointestinal stromal tumor; imatinib; gastrointestinal stromal tumors; proto-oncogene proteins c-kit; metastasis; gene expression; anemia; protein kinase inhibitor; bleeding; nausea; vomiting; incidence; genotype; weight reduction; drug resistance, neoplasm; protein tyrosine kinase; pyrimidines; abdominal pain; febrile neutropenia; rash; sarcoma; drug delivery systems; protein kinase inhibitors; liver failure; vatalanib; heat shock protein 90 inhibitor; gastrectomy; targeted therapy; optimal drug dose; piperazines; motesanib; gist; tyrosine kinase inhibitor; mammalian target of rapamycin inhibitor; nilotinib; protein kit; valatinib; abdominal mass; endoscopic biopsy; gastroesophageal reflux; periorbital edema; drugs, investigational; indoles; pyrroles |
| Journal Title: | Advances in Therapy |
| Volume: | 26 |
| Issue: | 9 |
| ISSN: | 0741-238X |
| Publisher: | Springer |
| Date Published: | 2009-09-01 |
| Start Page: | 826 |
| End Page: | 837 |
| Language: | English |
| DOI: | 10.1007/s12325-009-0067-9 |
| PUBMED: | 19802531 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 30 November 2010" - "CODEN: ADTHE" - "Source: Scopus" |
